Colorectal Neoplasms
647
72
97
300
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
79 trials with published results (12%)
Research Maturity
300 completed trials (46% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
9.3%
60 terminated out of 647 trials
83.3%
-3.2% vs benchmark
10%
66 trials in Phase 3/4
26%
79 of 300 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 300 completed trials
Clinical Trials (647)
Nudging Preventive Screening Via Message Framing and Bundling
First in Human Study of AZD9592 in Solid Tumors
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
Impact of SMS Messaging on Participation in Colorectal Cancer Screening.
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Phase I Platinum Based Chemotherapy Plus Indomethacin
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
AI-empowered Nudge to Improve Colonoscopy Uptake (AINC)
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Liquid Biopsy in Early Colorectal Lesions